Using the FDA-approved anti–CTLA-4 Ab that binds to human but not mouse protein, researchers were able to determine that binding of CTLA-4 efficiently induces Treg cell depletion and Fc receptor-dependent tumor rejection, rather than the previously accepted mechanism of blocking the interaction of B7 and CTLA-4. This evidence concerns the gene CTLA4 and neoplasm.